On October 8, 202, Chairman Jonathan Symonds said GlaxoSmithKline still plans to split its consumer division and increase the number of pharmaceutical experts and scientists on its board in 2022. In a call with investors Symonds said the UK pharmaceutical company will also name a new chair for its consumer business, which will be separated from its pharmaceutical and vaccines segments in mid-2022. The chairman, however, did not address activist investor Elliott's calls to replace CEO Emma Walmsley on a private investor call. In July, Elliott urged the company to find a successor for Walmsley, whom it accused of mismanaging the demerger of GlaxoSmithKline's consumer business.